Connexon Creative Immunology Newsletters,
Promising results were reported in a trial of engineered T cells in high-risk leukemia. http://ascopubs.org/doi/10.1200/JCO.2017.
Promising results were reported in a trial of engineered T cells in high-risk leukemia. http://ascopubs.org/doi/10.1200/JCO.2017.
Amazing results with new #CAR_T Studies seen in Journal of Clinical Oncology. @CLL Remission in 74% of patients! https://t.co/5Lb…